Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies. Phase 2: Assessment of the objective response rate (ORR), measured by RECIST 1.1 criteria as assessed by blinded independent central review (BICR).

Detailed Description
-----------------
Phase 1:The primary objective of the dose escalation portion of this study was to assess the safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin (mFOLFOX6) in advanced GI malignancies. The primary objective of the maximum tolerated dose (MTD) expansion phase (recommended phase 2 dose [RP2D]) of this study was to determine preliminary estimates of efficacy, measured by RECIST 1.1 criteria, for ADI-PEG 20 in combination with FOLFOX in hepatocellular carcinoma (HCC), gastro-esophageal cancer (GEC), and colorectal cancer (CRC). Phase 2: The primary objective of this single arm trial is ORR. Based on a two-sided exact test of a one-sample proportion with an alpha of 0.05, under a presumed ORR of 22%, there is 80% power to yield 95% confidence interval of 15-26%, which will require 46 objective responses in 225 subjects. A futility analysis will be described in the Statistical Analysis Plan.

Official Title
-----------------
Phase 1/2 Study of ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

Conditions
-----------------
Advanced Gastrointestinal (GI) Malignancies, Hepatocellular Carcinoma, Gastric Cancer, Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: ADI-PEG 20 plus modified FOLFOX6


Participation Criteria
=================
Eligibility Criteria
-----------------
Phase 2 HCC Subjects: Inclusion Criteria: Advanced histologically or cytologically proven HCC (except with prior liver transplantation). Treatment with at least 2 prior systemic therapy regimens. Child-Pugh grade A. Child-Pugh status should be determined based on clinical findings and laboratory data during the screening period (Appendix C). Measurable disease using RECIST 1.1 criteria (Appendix A). At least 1 measurable lesion must be present. Subjects who have received local-regional therapies are eligible, provided that they have either a target lesion which has not been treated with local therapy and/or the target lesion(s) within the field of the local regional therapy has shown an increase of ≥ 20% in size. Local-regional therapy must be completed at least 4 weeks prior to the baseline CT scan. ECOG performance status of 0 - 1. Expected survival of at least 3 months. Age ≥ 18 years. Fully recovered from any prior surgery and no major surgery within 4 weeks of initiating treatment. Surgery or procedure for placement of vascular access devices is exempt from this period. Subjects must agree to use at least one form of highly effective contraception or agree to refrain from intercourse for the duration of the study. Contraceptive use must be continued until at least 30 days after the last administration of ADI-PEG 20 and at least 90 days after the last administration of FOLFOX. For female subjects, a serum human chorionic gonadotropin (HCG) pregnancy test must be negative before entry into the study. If HCG pregnancy test is positive, further evaluation to rule out pregnancy must be performed according to GCP before this patient is claimed eligible. Informed consent must be obtained prior to study initiation. No concurrent investigational studies are allowed. Total bilirubin < 1.5 x upper limit of normal range. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal range. Absolute neutrophil count (ANC) > 1500/μL. Platelets > 75,000/μL. Serum uric acid ≤ 8 mg/dL (with or without medication control). Serum creatinine ≤ 1.5 x the upper limit of normal range, or, if serum creatinine >1.5 x the upper limit of normal range, then the creatinine clearance must be ≥ 60 mL/min/1.73 m2 (calculated using the Jelliffe equation: calculated creatinine clearance = 98 - 0.8 [age (yrs.) - 20] /serum creatinine (x 0.9 if female). Brain metastases are allowed if well controlled and without seizures. Serum albumin level ≥ 2.8 g/dL. Prothrombin time (PT)-international normalized ratio (INR): PT <6 seconds above control or INR <1.7. Subjects on Coumadin anti-coagulants are to receive only 1 point for their INR status. Subjects with active hepatitis B or C on anti-viremic compounds may remain on such treatment, except for interferon. Exclusion Criteria: A subject will not be eligible for study participation if he/she meets any of the exclusion criteria: Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within 7 days prior to the first dose of study treatment. Pregnancy or lactation. Expected non-compliance. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV), cardiac arrhythmia, or psychiatric illness. Subjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or ≤ Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and investigator may be allowed upon agreement with both. Subjects with history of another primary cancer, including co-existent second malignancy, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor with no known active disease present or in the opinion of the investigator will not affect patient outcome. Subjects who had been treated with ADI-PEG 20 previously. History of seizure disorder not related to underlying cancer. Known HIV positivity (testing not required). Known allergy to pegylated compounds. Known allergy to E. coli drug products (such as GMCSF). Known allergy to oxaliplatin or other platinum compounds. Prior grade 2 or higher neuropathy from prior platinum unless neuropathy is currently ≤ grade 1. Contraindications to fluorouracil Subjects with poor nutritional state. Known depressed bone marrow function. Subjects with potentially serious infections. Known allergy to fluorouracil.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ADI-PEG 20 plus modified FOLFOX6<br>Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) In combination with modified FOLFOX6, every 2 weeks, intravenous (IV) / IV bolus | Drug: ADI-PEG 20 plus modified FOLFOX6<br> <br> * Other names: pegargiminase;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate (ORR) | The percent of subjects who exhibit each level of tumor response, measured by RECIST 1.1 criteria as assessed by blinded independent central review. | Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival (PFS) | Time from the first dose until objective tumor progression or death from any cause | Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), 12 months anticipated | 
| Overall survival (OS) | The time from first treatment with ADI-PEG 20 until death or censoring | Date of first study drug administration through study completion | 
| Duration of response (DoR) | the time in weeks between the first occurrence of objective response and the development of progressive disease or death | From date of first response until the date of documented progression or date of death, 12 month in average | 
| Disease control rate (DCR) | the proportion of subjects at each post-baseline assessment who exhibit tumor response of complete response, partial response or stable disease | Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), up to 24 months. | 
| Pharmacodynamics | Blood levels of arginine and citrulline | At week 1, 5, 9, 13, 17, 21 prior to ADI-PEG 20 administration | 
| Pharmacokinetics Variable | Peripheral blood levels of ADI-PEG 20 | At week 1, 5, 9, 13, 17, 21 prior to ADI-PEG 20 administration | 
| Immunogenicity | antibodies to ADI-PEG 20 | At week 1, 5, 9, 13, 17, 21 prior to ADI-PEG 20 administration | 
| AFP (alpha feto-protein) changes | Maximal percent changes of AFP during the course of study compared to AFP at baseline | At baseline, week3, 7, 11, 15, 19, 23 and end of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
argininosuccinate synthetase, arginine, arginine deiminase